CL2019000820A1 - Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134) - Google Patents

Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)

Info

Publication number
CL2019000820A1
CL2019000820A1 CL2019000820A CL2019000820A CL2019000820A1 CL 2019000820 A1 CL2019000820 A1 CL 2019000820A1 CL 2019000820 A CL2019000820 A CL 2019000820A CL 2019000820 A CL2019000820 A CL 2019000820A CL 2019000820 A1 CL2019000820 A1 CL 2019000820A1
Authority
CL
Chile
Prior art keywords
compounds
compositions
divisional application
arginase activity
inhibit arginase
Prior art date
Application number
CL2019000820A
Other languages
English (en)
Inventor
Eric B Sjogren
Jim Li
Zandt Michael Van
Darren Whitehouse
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CL2019000820A1 publication Critical patent/CL2019000820A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA INVENCIÓN SE REFIERE A UNA NUEVA CLASE DE COMPUESTOS QUE EXHIBEN ACTIVIDAD INHIBIDORA DE LA ACTIVIDAD HACIA LA ARGINASA, Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DE LA INVENCIÓN. TAMBIÉN SE PROPORCIONAN EN EL PRESENTE DOCUMENTO LOS MÉTODOS PARA TRATAR EL CÁNCER CON LOS INHIBIDORES DE ARGINASA DE LA INVENCIÓN.
CL2019000820A 2015-10-30 2019-03-28 Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134) CL2019000820A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US201662323034P 2016-04-15 2016-04-15

Publications (1)

Publication Number Publication Date
CL2019000820A1 true CL2019000820A1 (es) 2019-08-09

Family

ID=58631120

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2018001134A CL2018001134A1 (es) 2015-10-30 2018-04-27 Composiciones y métodos para inhibir la actividad arginasa
CL2019000819A CL2019000819A1 (es) 2015-10-30 2019-03-28 Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2019000820A CL2019000820A1 (es) 2015-10-30 2019-03-28 Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2019000821A CL2019000821A1 (es) 2015-10-30 2019-03-28 Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2018001134A CL2018001134A1 (es) 2015-10-30 2018-04-27 Composiciones y métodos para inhibir la actividad arginasa
CL2019000819A CL2019000819A1 (es) 2015-10-30 2019-03-28 Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019000821A CL2019000821A1 (es) 2015-10-30 2019-03-28 Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)

Country Status (36)

Country Link
US (4) US10065974B2 (es)
EP (3) EP3693375B1 (es)
JP (3) JP6833844B2 (es)
KR (2) KR20220118559A (es)
CN (4) CN113201002A (es)
AU (3) AU2016343656B2 (es)
BR (3) BR122020022280B1 (es)
CA (1) CA3003271A1 (es)
CL (4) CL2018001134A1 (es)
CO (1) CO2018004750A2 (es)
CR (3) CR20210389A (es)
CY (1) CY1123557T1 (es)
DK (2) DK3368541T3 (es)
EA (1) EA038276B1 (es)
EC (1) ECSP18040250A (es)
ES (3) ES2910928T3 (es)
HR (1) HRP20201046T1 (es)
HU (1) HUE054972T2 (es)
IL (3) IL258731B (es)
LT (1) LT3368541T (es)
MA (2) MA50636A (es)
MD (1) MD3368541T2 (es)
MX (1) MX2018005294A (es)
MY (1) MY201783A (es)
NZ (1) NZ742742A (es)
PH (2) PH12022551082A1 (es)
PL (1) PL3368541T3 (es)
PT (1) PT3368541T (es)
RS (1) RS60695B1 (es)
SG (4) SG10201911402YA (es)
SI (1) SI3368541T1 (es)
SM (1) SMT202000469T1 (es)
TW (3) TWI710565B (es)
UA (1) UA125289C2 (es)
WO (1) WO2017075363A1 (es)
ZA (4) ZA201803556B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012027034B1 (pt) 2010-04-22 2020-10-13 Mars, Incorporated compostos inibidores de arginase, composição farmacêutica compreendendo o referido composto, método in vitro para inibição de arginase i e ii e uso do referido composto
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
EP3842442B1 (en) 2016-12-22 2023-11-01 Precision Pharmaceuticals, Inc. Compositions and methods for inhibiting arginase activity
US10494339B2 (en) 2017-05-12 2019-12-03 Calithera Biosciences, Inc. Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide
US11655260B2 (en) 2017-12-22 2023-05-23 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
CN117186134A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
US12054500B2 (en) 2018-03-05 2024-08-06 Arcus Biosciences, Inc. Arginase inhibitors
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2020102646A2 (en) 2018-11-16 2020-05-22 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
WO2020131598A1 (en) 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
US20220251116A1 (en) * 2019-02-06 2022-08-11 Guangdong Newopp Biopharmaceuticals Co., Ltd. Alkylboronic acids as arginase inhibitors
US11420966B2 (en) * 2019-05-02 2022-08-23 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as JAK inhibitors
JP7579324B2 (ja) * 2019-07-23 2024-11-07 アストラゼネカ・アクチエボラーグ アルギナーゼ阻害剤及びその使用方法
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
CN115135385B (zh) 2019-11-12 2024-05-10 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
WO2021141751A1 (en) * 2020-01-07 2021-07-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
BR112023000047A2 (pt) 2020-07-02 2023-03-14 Incyte Corp Compostos de ureia tricíclicos como inibidores da v617f da jak2
WO2022016195A1 (en) 2020-07-17 2022-01-20 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
KR20240163688A (ko) 2022-03-17 2024-11-19 인사이트 코포레이션 Jak2 v617f 억제제로서의 삼환계 우레아 화합물
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors
KR20250169642A (ko) 2023-03-13 2025-12-03 인사이트 코포레이션 키나제 억제제로서의 이환식 우레아
WO2026076207A1 (en) 2024-10-04 2026-04-09 Incyte Corporation Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
EP1299398A1 (en) 2000-07-06 2003-04-09 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DE602004023516D1 (de) 2003-08-07 2009-11-19 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1915143A4 (en) 2005-07-01 2009-11-11 Univ Johns Hopkins ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE
WO2009008415A1 (ja) 2007-07-12 2009-01-15 Sanyo Denki Co., Ltd. 二重反転式軸流送風機
EP2214660A2 (en) * 2007-10-12 2010-08-11 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions
CA2722992A1 (en) * 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
TR201910726T4 (tr) * 2009-01-26 2019-08-21 Astrazeneca Uk Ltd Arginaz inhibitörleri ve kullanım yöntemleri.
BR112012027034B1 (pt) 2010-04-22 2020-10-13 Mars, Incorporated compostos inibidores de arginase, composição farmacêutica compreendendo o referido composto, método in vitro para inibição de arginase i e ii e uso do referido composto
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
CN103402549A (zh) 2010-12-31 2013-11-20 考瑞多制药公司 精氨酸酶抑制剂及其使用方法
AU2012326109A1 (en) 2011-10-19 2014-05-29 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
IN2014DN09678A (es) 2012-04-18 2015-07-31 Mars Inc
EP2914263A4 (en) * 2012-11-02 2016-04-27 Pharmacyclics Inc ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR
TWI617309B (zh) * 2013-10-25 2018-03-11 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
EP3270907A1 (en) 2015-03-20 2018-01-24 Sammy Oyoo OPIYO Use of suramin and arginase inhibitors in malignant neoplasia
WO2016210106A1 (en) 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Also Published As

Publication number Publication date
ZA201907091B (en) 2021-05-26
DK4011887T3 (da) 2024-10-28
SMT202000469T1 (it) 2020-11-10
CR20210390A (es) 2021-10-19
UA125289C2 (uk) 2022-02-16
US10844080B2 (en) 2020-11-24
MA43131B1 (fr) 2020-07-29
PH12022551082A1 (en) 2023-03-13
RS60695B1 (sr) 2020-09-30
IL288225A (en) 2022-01-01
EP3368541A1 (en) 2018-09-05
BR122020022280B1 (pt) 2022-05-03
DK3368541T3 (da) 2020-06-29
EP4011887A1 (en) 2022-06-15
BR122020022275B1 (pt) 2022-05-03
JP7032583B2 (ja) 2022-03-08
CA3003271A1 (en) 2017-05-04
TWI775556B (zh) 2022-08-21
US20210061822A1 (en) 2021-03-04
MX2018005294A (es) 2018-09-21
TW201726692A (zh) 2017-08-01
US10065974B2 (en) 2018-09-04
AU2016343656B2 (en) 2020-09-17
MY201783A (en) 2024-03-18
IL281503B (en) 2022-01-01
EP3368541A4 (en) 2019-07-17
ES2910928T3 (es) 2022-05-17
CL2019000819A1 (es) 2019-08-09
TW202110858A (zh) 2021-03-16
KR102434308B1 (ko) 2022-08-19
ECSP18040250A (es) 2018-10-31
MA50636A (fr) 2021-04-14
EA201891057A1 (ru) 2018-12-28
JP6833844B2 (ja) 2021-02-24
JP2021075543A (ja) 2021-05-20
CO2018004750A2 (es) 2018-10-31
TW202146028A (zh) 2021-12-16
EA038276B1 (ru) 2021-08-04
EP3693375A1 (en) 2020-08-12
KR20220118559A (ko) 2022-08-25
AU2016343656A1 (en) 2018-06-07
ES2808988T3 (es) 2021-03-02
CN113150016A (zh) 2021-07-23
HK1252560A1 (en) 2019-05-31
MD3368541T2 (ro) 2020-09-30
IL258731B (en) 2021-04-29
US10851118B2 (en) 2020-12-01
PH12018500899A1 (en) 2018-10-29
CR20180282A (es) 2018-11-30
JP2022071010A (ja) 2022-05-13
SG10201911402YA (en) 2020-02-27
AU2020286278A1 (en) 2021-01-14
TWI734630B (zh) 2021-07-21
EP3693375B1 (en) 2022-02-16
AU2020286278B2 (en) 2022-03-17
AU2022203703A1 (en) 2022-06-16
US20170121352A1 (en) 2017-05-04
CL2018001134A1 (es) 2018-10-26
SG11201802961PA (en) 2018-05-30
CN113150015A (zh) 2021-07-23
SG10201911406TA (en) 2020-01-30
CN108271371A (zh) 2018-07-10
LT3368541T (lt) 2020-09-25
HRP20201046T1 (hr) 2020-10-16
CN108271371B (zh) 2021-02-09
KR20180084063A (ko) 2018-07-24
ZA201907092B (en) 2021-04-28
PH12018500899B1 (en) 2023-02-08
SI3368541T1 (sl) 2020-10-30
BR112018008746A2 (pt) 2018-10-30
CN113201002A (zh) 2021-08-03
PT3368541T (pt) 2020-07-06
CR20210389A (es) 2021-09-16
WO2017075363A1 (en) 2017-05-04
EP3368541B1 (en) 2020-05-27
ES2991555T3 (es) 2024-12-04
ZA201803556B (en) 2021-02-24
EP4011887B1 (en) 2024-07-31
HUE054972T2 (hu) 2021-10-28
ZA201907093B (en) 2021-03-31
CL2019000821A1 (es) 2019-08-09
NZ742742A (en) 2023-04-28
SG10202003966RA (en) 2020-06-29
CY1123557T1 (el) 2022-03-24
BR112018008746B1 (pt) 2021-11-16
PL3368541T3 (pl) 2020-11-02
IL258731A (en) 2018-06-28
TWI710565B (zh) 2020-11-21
IL281503A (en) 2021-04-29
JP2018533582A (ja) 2018-11-15
US20180346489A1 (en) 2018-12-06
BR112018008746A8 (pt) 2019-02-26
US20200223872A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
CL2019000821A1 (es) Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
CL2020002919A1 (es) Inhibidores de mcl-1
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CL2020000169A1 (es) Compuestos macrocíclicos y usos de los mismos.
CR20150316A (es) Compuestos y sus métodos de empleo
CO2018013077A2 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2017002656A (es) Compuestos que inhiben la proteína mcl-1.
MX2021009673A (es) Moduladores de ror-gamma.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2017011018A (es) Inhibicion de la actividad de olig2.